Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 10/20 | 0.36 |
| ▸ | RAB9A | P51151 | 10/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL624251 | 0.74 | L3MBTL1 (0.53) | MTORNPC1RAB9AABL1SMN1; SMN2 | |
| SCHEMBL31627738 | 0.71 | MTOR (0.44) | MTORNPC1RAB9ATP53MAPK1 | |
| SCHEMBL15907221 | 0.70 | MTOR (0.56) | MTORNPC1RAB9ATP53POLB | |
| SCHEMBL15981013 | 0.69 | HDAC6 (0.38) | — | |
| SCHEMBL15907219 | 0.68 | MTOR (0.57) | MTORNPC1RAB9ATP53POLB | |
| SCHEMBL31511994 | 0.67 | GSK3B (0.46) | MTORMAPK1 | |
| SCHEMBL15907196 | 0.67 | NPC1 (0.36) | NPC1RAB9ATP53POLBKMT2A | |
| SCHEMBL15907218 | 0.66 | MTOR (0.43) | MTORNPC1RAB9ATP53POLB | |
| SCHEMBL15907220 | 0.66 | MAP3K5 (0.43) | MTORNPC1RAB9ATP53MAPK1 | |
| SCHEMBL3466637 | 0.66 | MTOR (0.43) | MTORNPC1RAB9ATP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | MTOR 348/4885NPC1 3370/4885RAB9A 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.